NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of FireEye, Inc. (NASDAQ: FEYE), CSRA Inc. (NYSE: CSRA), Concho Resources Inc. (NYSE: CXO), Trevena, Inc. (NASDAQ: TRVN), Five Prime Therapeutics, Inc. (NASDAQ: FPRX), and Endocyte, Inc. (NASDAQ: ECYT), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

FEYE DOWNLOAD: http://MarketSourceResearch.com/register/?so=FEYE CSRA DOWNLOAD: http://MarketSourceResearch.com/register/?so=CSRA CXO DOWNLOAD: http://MarketSourceResearch.com/register/?so=CXO TRVN DOWNLOAD: http://MarketSourceResearch.com/register/?so=TRVN FPRX DOWNLOAD: http://MarketSourceResearch.com/register/?so=FPRX ECYT DOWNLOAD: http://MarketSourceResearch.com/register/?so=ECYT

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Market Source Research, available for free download at the links above, examine FireEye, Inc. (NASDAQ: FEYE), CSRA Inc. (NYSE: CSRA), Concho Resources Inc. (NYSE: CXO), Trevena, Inc. (NASDAQ: TRVN), Five Prime Therapeutics, Inc. (NASDAQ: FPRX), and Endocyte, Inc. (NASDAQ: ECYT) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed November 28th, 2017. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

FIREEYE, INC. (FEYE) REPORT OVERVIEW

FireEye's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, FireEye reported revenue of $189.60MM vs $186.41MM (up 1.71%) and basic earnings per share -$0.41 vs -$0.75. For the twelve months ended December 31st, 2016 vs December 31st, 2015, FireEye reported revenue of $714.11MM vs $622.97MM (up 14.63%) and basic earnings per share -$2.94 vs -$3.50. FireEye is expected to report earnings on February 1st, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.22. The estimated EPS forecast for the next fiscal year is -$0.86 and is expected to report on February 1st, 2018.

To read the full FireEye, Inc. (FEYE) report, download it here: http://MarketSourceResearch.com/register/?so=FEYE

-----------------------------------------

CSRA INC. (CSRA) REPORT OVERVIEW

CSRA's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, CSRA reported revenue of $1,272.00MM vs $1,263.00MM (up 0.71%) and basic earnings per share $0.46 vs $0.46 (unchanged). For the twelve months ended March 31st, 2017 vs March 31st, 2016, CSRA reported revenue of $4,993.00MM vs $4,250.00MM (up 17.48%) and basic earnings per share $1.86 vs $0.54 (up 244.44%). CSRA is expected to report earnings on February 6th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.48. The estimated EPS forecast for the next fiscal year is $2.08 and is expected to report on May 23rd, 2018.

To read the full CSRA Inc. (CSRA) report, download it here: http://MarketSourceResearch.com/register/?so=CSRA

-----------------------------------------

CONCHO RESOURCES INC. (CXO) REPORT OVERVIEW

Concho Resources' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Concho Resources reported revenue of $627.00MM vs $430.00MM (up 45.81%) and basic earnings per share -$0.77 vs -$0.38. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Concho Resources reported revenue of $1,634.99MM vs $1,803.57MM (down 9.35%) and basic earnings per share -$10.85 vs $0.54. Concho Resources is expected to report earnings on February 20th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.20. The estimated EPS forecast for the next fiscal year is $2.31 and is expected to report on February 20th, 2018.

To read the full Concho Resources Inc. (CXO) report, download it here: http://MarketSourceResearch.com/register/?so=CXO

-----------------------------------------

TREVENA, INC. (TRVN) REPORT OVERVIEW

Trevena's Recent Financial Performance

For the twelve months ended December 31st, 2016 vs December 31st, 2015, Trevena reported revenue of $3.75MM vs $6.25MM (down 40.00%) and basic earnings per share -$1.97 vs -$1.15. Trevena is expected to report earnings on March 14th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.67. The estimated EPS forecast for the next fiscal year is -$0.95 and is expected to report on March 14th, 2018.

To read the full Trevena, Inc. (TRVN) report, download it here: http://MarketSourceResearch.com/register/?so=TRVN

-----------------------------------------

FIVE PRIME THERAPEUTICS, INC. (FPRX) REPORT OVERVIEW

Five Prime Therapeutics' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Five Prime Therapeutics reported revenue of $8.33MM vs $6.68MM (up 24.75%) and basic earnings per share -$1.54 vs -$0.72. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Five Prime Therapeutics reported revenue of $30.69MM vs $379.80MM (down 91.92%) and basic earnings per share -$2.44 vs $9.73. Five Prime Therapeutics is expected to report earnings on February 22nd, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.73. The estimated EPS forecast for the next fiscal year is -$5.00 and is expected to report on February 22nd, 2018.

To read the full Five Prime Therapeutics, Inc. (FPRX) report, download it here: http://MarketSourceResearch.com/register/?so=FPRX

-----------------------------------------

ENDOCYTE, INC. (ECYT) REPORT OVERVIEW

Endocyte's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Endocyte reported revenue of $0.03MM vs $0.03MM (unchanged) and basic earnings per share -$0.55 vs -$0.21. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Endocyte reported revenue of $0.07MM vs $0.07MM (unchanged) and basic earnings per share -$1.04 vs -$0.98. Endocyte is expected to report earnings on March 9th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.26. The estimated EPS forecast for the next fiscal year is -$0.91 and is expected to report on March 9th, 2018.

To read the full Endocyte, Inc. (ECYT) report, download it here: http://MarketSourceResearch.com/register/?so=ECYT

-----------------------------------------

ABOUT MARKET SOURCE RESEARCH

Market Source Research delivers the key research reports that help serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.

REGISTERED MEMBER STATUS

Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at [email protected].

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Hugo Moreau, Media Department Office: +1 (704) 343-6361 E-mail: [email protected]

© 2017 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Source: Market Source Research

Press Releases